GEHC in the 13F filings
Ge Healthcare Technologies I · CUSIP 36266G107
- Quarter end
- 31 Dec 2024
- the date the book describes
- Filed
- 14 Feb 2025
- latest of these filings; the earliest 10 Feb 2025
- Managers listing it
- 18
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q3 2024 and Q4 2024; 16 listed it in both
- Shares listed
- 112,977,768
- combined, among listed positions
- Reported value
- $8.8bn
- combined, at the quarter end
Among the 94 comparable managers: 10 buyers (opened or added shares) and 6 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing GEHC in Q4 2024
18 of 18 holders
Largest increases and reductions, by shares
Increases
- Capital Research Global Investorsexisting position · 60,832,004 shares now+2,608,066
- Harris Associates LPexisting position · 4,247,304 shares now+2,401,049
- Invesco Ltdexisting position · 8,067,927 shares now+1,252,613
- D1 Capital Partners LPexisting position · 3,486,584 shares now+629,270
- MFS Investment Managementexisting position · 1,310,631 shares now+312,088
Reductions
- Egerton Capital UK LLPexisting position · 4,572,382 shares now-1,107,639
- T. Rowe Price Associates Incexisting position · 6,164,671 shares now-408,038
- AllianceBernstein LPexisting position · 6,127,669 shares now-220,133
- Discovery Capital Management LLCexisting position · 50,000 shares now-160,550
- Bridgewater Associates LPexisting position · 32,019 shares now-24,558
New positions and exits
New (2)
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2022 | 1 | $371m | n.a. | n.a. |
| Q1 2023 | 13 | $8.0bn | n.a. | n.a. |
| Q2 2023 | 21 | $8.7bn | n.a. | n.a. |
| Q3 2023 | 14 | $6.6bn | n.a. | n.a. |
| Q4 2023 | 13 | $7.3bn | 7 | 8 |
| Q1 2024 | 17 | $9.7bn | 10 | 5 |
| Q2 2024 | 17 | $8.0bn | 9 | 5 |
| Q3 2024 | 20 | $10.7bn | 9 | 11 |
| Q4 2024 | 18 | $8.8bn | 10 | 6 |
| Q1 2025 | 18 | $8.4bn | 9 | 11 |
| Q2 2025 | 22 | $7.2bn | 15 | 6 |
| Q3 2025 | 14 | $6.3bn | 6 | 9 |
| Q4 2025 | 13 | $8.1bn | 17 | 22 |
| Q1 2026 | 11 | $6.3bn | 19 | 18 |
| Q2 2026 | 9 | $4.9bn | 24 | 17 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
GEHC and LLY →GEHC and JNJ →GEHC and VRTX →Choose a stock to compare with GEHC →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own GEHC, latest filings →Back to the 13F Explorer →